Karl Anderson

Karl’s interests span synthetic biology, metabolic engineering and their applications in bioproduction. During his undergraduate years, he delved into enzyme engineering research. Following graduation, he contributed to the development of T-cell therapies for cancer treatment at Bristol Myers Squibb. He holds a B.S. in biology and chemistry from the University of Washington.